Your Messages Inbox
Your Article Summary
See Latest ArticlesMorphotek, Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, A Monoclonal Antibody for the Treatment of Cancer
Morphotek, 06/16/09
Morphotek, Inc., a subsidiary of Eisai Corporation of North America, announced that the U.S. Food and Drug Administration cleared its investigational new drug application to study MORAb-004 in the treatment of patients with solid tumors. MORAb-004 targets endosialin, a protein expressed on cells associated with tumors and tumor blood vessel cells.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
US FDA approves SEROQUEL XR for add-on treatment of Major Depressive Disorder
AstraZeneca, 12/07/09
FDA Approves Initiation of Clinical Studies in the U.S. for T2000, Taros Proprietary Non-Sedating Barbiturate Compound
Taro Pharmaceuticals USA, 12/07/09
Article Search
Sponsor